Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 4/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 5/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 5/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25128559 | 0.77 | ANO1 (0.35) | ANO1KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL25128558 | 0.73 | ANO1 (0.34) | ANO1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25128563 | 0.72 | — | — | |
| SCHEMBL4181845 | 0.71 | MAOB (0.38) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL25128562 | 0.71 | — | — | |
| SCHEMBL7334464 | 0.71 | NOTUM (0.35) | ANO1PDK1PDK2PDK3PDK4 | |
| SCHEMBL8403380 | 0.70 | ADRA2A (0.38) | ANO1PDK1PDK2PDK3PDK4 | |
| SCHEMBL8545657 | 0.67 | PARP1 (0.49) | KMT2AALDH1A1MEN1PTGESMAPT | |
| SCHEMBL25128560 | 0.66 | F2 (0.35) | ANO1ALDH1A1ADRA2A | |
| SCHEMBL18181784 | 0.65 | AAK1 (0.33) | KMT2AHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| EP-4159723-A1 | NOVEL THYROID HORMONE ß RECEPTOR AGONIST | Chengdu Kanghong Pharmaceutical Co., Ltd. (CN) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257367-A1 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST | THRB, THRA, TSHR | ANO1 4073/4885PDK1 1446/4885PDK2 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.